Skip to main content

Advertisement

SpringerLink
Log in

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.

Methods

Records of 680 patients with HER2-positive early breast cancer who received adjuvant trastuzumab plus chemotherapy were obtained and patients were followed up to compare the disease-free survival (DFS) outcome of 9 weeks versus 1 year trastuzumab.

Results

Nine weeks and 1 year trastuzumab was given to 202 (29.7 %) and 478 (70.3 %) patients, respectively. There was a significantly lower rate of patients with negative lymph nodes in the 9-week trastuzumab group. At median 3 years of follow-up from the date of starting trastuzumab, the DFS rates were 88.6 and 85.6 %, respectively (p = 0.670). When adjusted for all the prognostic factors that were significant on univariate analysis, again there was no significant difference in DFS between the groups (HR 0.675; 95 % CI 0.370–1.231; p = 0.200). Cardiac toxicity defined as a ≥15 % decrease in LVEF was significantly higher in the 1-year trastuzumab group (1.88 % versus none for 1-year and 9-week trastuzumab groups, respectively; p = 0.050).

Conclusion

The results of this observational study suggest that DFS outcome of 9 weeks of adjuvant trastuzumab may be comparable to 1 year adjuvant trastuzumab: this needs confirmation by randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Piccart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.

    Article  Google Scholar 

  2. Edward H, Romond EH, Perez EH, Bryant J, Suman VJ, Geyer CE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

    Article  Google Scholar 

  3. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Goldhirsch A, Piccart-Gebhart MJ, Procter M, de Azambuja E, Weber HA, Untch M, et al. HERA trial: 2 years versus 1 year trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast breast cancer at 8 years of median follow-up. Ann Oncol. 2012;23(9 suppl): Abstract LBA6_PR.

  5. Sledge GW, O’Neill A, Thor A, Kahanic SP, Zander. PJ, Davidson N. Adjuvant trastuzumab: long-term results of E2198. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX 2006: Abstract 2075.

  6. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009;27:5685–92.

    Article  PubMed  CAS  Google Scholar 

  7. Pivot XB, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T. 6 Months versus 12 months of adjuvant trastuzumab for patients with early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741–7.

    Article  PubMed  CAS  Google Scholar 

  8. Icli F, Altundağ K, Coşkun U, Paydas S, Basaran G, Saip P, et al. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: an observational study of Turkish Oncology Group. J Clin Oncol. 2011;29 (15 suppl): Abstract 629.

    Google Scholar 

  9. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29:4491–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Shojaci S, Gardaneh M, Shamabadi AR. Target points in trastuzumab resistance. International Journal of Breast Cancer. vol 2012, Article ID 761917, 2012. doi:10.1155/2012/761917.

  11. Yoshida R, Tazawa H, Hashimoto Y, Yano S, Onishi T, Sasaki T, et al. Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extacellular domain in human cancer cells. Cancer Immunol Immunother. 2012;61:1905–16.

    Article  PubMed  CAS  Google Scholar 

  12. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, et al. Docetaxel, cisplatin and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006;24:1831–8.

    Article  PubMed  CAS  Google Scholar 

  13. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15:7381–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhász I, Vereb G, et al. Trastuzumab causes antibody dependant cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007;6:2065–72.

    Article  PubMed  CAS  Google Scholar 

  15. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenograft on therapy with humanised monoclonal antibody to HER2 receptor and DNA-reactive drugs. Oncogene. 1998;17:2235–49.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Financial support for statistical analysis was obtained from the Turkish Medical Oncoloy Society.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Ankara Üniversitesi Tıp Fakültesi; Tıbbi Onkoloji BD, Dikimevi, Ankara, 06590, Turkey

    Fikri İçli, Hakan Akbulut & Handan Onur

  2. Hacettepe University Medical School, Ankara, Turkey

    Kadri Altundağ & Nilüfer Güler

  3. Çukurova University Medical School, Adana, Turkey

    Semra Paydaş

  4. Marmara University Medical School, Istanbul, Turkey

    Gül Başaran

  5. İstanbul University Oncology Institute, Istanbul, Turkey

    Pınar Saip & Yeşim Eralp

  6. Erciyes University Medical School, Kayseri, Turkey

    Gamze G. Doğu & Metin Özkan

  7. Ege University Medical School, Izmir, Turkey

    Rüçhan Uslu, Canfeza Sezgin & Erhan Gökmen

  8. Gaziantep University Medical School, Gaziantep, Turkey

    Alper Sevinç

  9. İstanbul University Cerrahpaşa Medical School, Istanbul, Turkey

    Nil M. Mandel

  10. Ankara Research and Treatment Hospital, Ankara, Turkey

    Mustafa Altınbaş

  11. Dicle University Medical School, Diyarbakır, Turkey

    Abdurrahman Işıkdoğan

  12. Kocaeli University Medical School, İzmit, Turkey

    Kazım Uygun

  13. Okmeydanı Research and Treatment Hospital, Istanbul, Turkey

    Zeki Üstüner

  14. Pamukkale University Medical School, Denizli, Turkey

    Arzu Yaren

  15. Dokuz Eylul University Medical School, Izmir, Turkey

    Binnaz Demirkan

  16. Gazi University Medical School, Ankara, Turkey

    Uğur Coşkun & Alper Ata

  17. Mersin University Medical School, Mersin, Turkey

    Ali Arican

Authors
  1. Fikri İçli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kadri Altundağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakan Akbulut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Semra Paydaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gül Başaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pınar Saip
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gamze G. Doğu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yeşim Eralp
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rüçhan Uslu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alper Sevinç
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Handan Onur
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nil M. Mandel
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Canfeza Sezgin
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mustafa Altınbaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Nilüfer Güler
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Abdurrahman Işıkdoğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Erhan Gökmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Kazım Uygun
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Zeki Üstüner
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Arzu Yaren
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Binnaz Demirkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Uğur Coşkun
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Alper Ata
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Metin Özkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Ali Arican
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fikri İçli.

About this article

Cite this article

İçli, F., Altundağ, K., Akbulut, H. et al. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer 22, 480–485 (2015). https://doi.org/10.1007/s12282-013-0506-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-013-0506-y

Keywords

Search

Navigation